Global Guillain-Barre Syndrome Treatment Market Report and Forecast 2024-2032

Guillain-Barre Syndrome Treatment Market Size

The Guillain-Barre syndrome treatment market is estimated to grow at a CAGR of 5.4% during the forecast period of 2024-2032, driven by increasing technological advancements propelling the market.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Guillain-Barre Syndrome Treatment Market Outlook

• The market growth is driven by the emphasis on developing new and effective treatment modalities that focus on specific molecular targets of Guillain-Barre syndrome pathology.

• Joint ventures between academic and biotech companies aimed at integrating system-oriented programmes to offer targeted therapeutic strategies is amongst major market trends.

• Increasing efforts to apply HEOR strategies for assessing the long-term effectiveness and value-based outcomes of the GBS therapeutic interventions is also expected to boost the market value in coming years.

Guillain-Barre Syndrome Treatment Market Overview

Guillain-Barré Syndrome (GBS) is an autoimmune, polycentral, rare peripheral nerve disorder, which affects large nerves outside the brain and spinal cord. It can lead to muscle weakness and paralysis, amongst a range of other fatal complications. Usually, the initial signs include non-serious shocks and initial paralysis of legs, which later affects arms and upper body parts. Although the cause of this diseases unknown, GBS syndrome commonly develops after an individual has been exposed to a bacterial or viral infection. Possible options for treatment include the identification of entirely differentiated neurological techniques to manage some of the symptoms, minimize inflammation, and encourage axon regeneration.

Guillain-Barre Syndrome Treatment Market Growth Drivers

Increased cases of Guillain-Barré Syndrome Drive the Market in the Forecast Period

The rising prevalence of the condition is driving the demand for effective treatment alternatives. GBS syndrome is generally associated with proximal and distal muscle weakness especially of the limbs, with accompanying diminished or absent reflexes, sensorial changes, and rarely cranial neuropathies. This particularly, is a very fast developing disease because of nerve inflammation that results in paralyzed muscles and muscles weakness and often results to total paralysis in patients. While the specific factor has not yet been determined, GBS syndrome is mostly triggered by a digestive or respire infection. To prevent comorbidities and mortality rates associated with the condition, researchers and scientists are actively working on developing precise and efficient treatment.

Modernization of Medical Equipment Leading to Accurate Diagnosis

As the technology progresses, diagnosis of GBS syndrome has become comparatively accurate and much faster. For instance, neuroimaging technology enabled with refined protocols and specialized biomarkers have all made it easier for healthcare professionals to diagnose GBS syndrome. Prompt and accurate diagnosis is highly essential since it can assist in early treatment of the disease and avoid severe consequences. Such advancements in technology are therefore instrumental to provide better and efficient diagnostics for GBS syndrome and boost its treatment market as well.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Guillain-Barre Syndrome Treatment Market Trends

Recent Developments in Guillain-Barre Syndrome Treatment Market

In October, 2023 Annexon Inc. achieved a significant milestone as the European Medicine Agency (EMA) granted orphan drug designation to ANX005 for treating Guillain-Barré Syndrome (GBS). ANX005, a humanized monoclonal antibody, targets C1q to stop complement-mediated inflammation and neuronal damage in GBS syndrome. The designation was based on a notable comparative efficacy analysis showing early muscle strength improvement compared to standard IVIg therapy, promising enhanced outcomes for GBS syndrome patients.

In March 2023, Hansa Biopharma completed enrollment in its phase 2 study of imlifidase in GBS syndrome. The phase II evaluated safety, tolerability, and efficacy in combination with standard (intravenous immunoglobulin) IVIg therapy. It was administered to patients before the standard of care.

Guillain-Barre Syndrome Treatment Market Segmentation

Market Breakup by Type

• Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)

• Miller Fisher Syndrome (MFS)

• Acute Motor Axonal Neuropathy (AMAN)

Market Breakup by Treatment

• Intravenous Immunoglobulin

• Plasma Exchange (Plasmapheresis)

• Others

Market Breakup by Route of Administration

• Parenteral

• Oral

• Others

Market Breakup by Gender

• Male

• Female

Market Breakup by Patient Type

• Adult

• Pediatric

Market Breakup by End User

• Hospitals

• Specialty Clinics

• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

• India

Guillain-Barre Syndrome Treatment Market Share

Intravenous Immunoglobulin is Anticipated to the Have Largest Market Share Based on Treatment

Based on the market segmentation by treatment, the market is divided into intravenous immunoglobulin, plasma exchange (plasmapheresis) and others. Intravenous immunoglobulin (IVIG) involves the application of an antibodies solution to manage the condition. The preference for this treatment can also be attributed to its faster absorption, leading to higher efficacy compared to other options. Wide availability of the IVIG products like Gamunex, Gammagard and Privigen also boosts the market share of this segment. Further, the rising research activities on IVIG are anticipated to contribute to the overall GBS syndrome treatment market growth.

Males Lead the Market Share Based on Gender

Based on gender, the segmentation includes males and females. The male to female incidence ratio is 1.5:1 for the condition. Hence, males are likely to lead the market share in the forecast period, owing to higher susceptibility of disease occurrence.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Guillain-Barre Syndrome Treatment Market by Region

Regionally, the market report offers insights on United States, EU-4 (Germany, France, Italy, and Spain), United Kingdom, Japan as well as India. The annual incidence in the United States population is around 1.2-3 per 100,000 individuals, out of which 8.6 cases per 100,000 occur at the age of 70-79 years. High prevalence rate, shift in the lifestyle and a rise in the per capita health expenditure are likely to impact the United States market share positively in the forecast period.

In United States and European countries, acute inflammatory demyelinating polyradiculoneuropathy (AIDP) has higher occurrence, while countries like Japan witnesses more cases of acute motor axonal neuropathy (AMAN). According to epidemiologic studies, Japan has a greater percentage of GBS syndrome cases in comparison to United States and European countries. With a robust medical research and development infrastructure, the region is expected to lead the market share for GBS syndrome treatment in the forecast period.

Leading Players in the Global Guillain-Barre Syndrome Treatment Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding, and investment analysis, along with partnership and collaborations analysis by the leading players. The major companies in the market are as follows:

CSL Behring

Established in the year 2007 and headquartered in Pennsylvania, United States, this company has a special neuromuscular therapy line with intravenous immunoglobulins (IVIg) for GBS syndrome treatment.

OctaPharma AG

Founded in 1983 and headquartered in Lachen, Swutzerland. The company’s plasma-derived immunoglobulin therapy specialises in GBS syndrome which include immunological disorders.

Annexon Biosciences

This is an American biotechnology company that was established in the year 2011 with its headquarters located in California, United States. The company has a product pipeline under investigation for GBS syndrome.

Other market players include Cellenkos Inc., and Hansa Biopharma AB.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

Key Questions Answered in the Guillain-Barre Syndrome Treatment Market

• What was the global Guillain-Barre syndrome treatment market value in 2023?
• What is the global Guillain-Barre syndrome treatment market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What are the major factors aiding the global Guillain-Barre syndrome treatment market demand? 
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• What are the major global Guillain-Barre syndrome treatment market trends?
• How does the rise in the geriatric population impact the market size?
• Who are the key players involved in the Guillain-Barre syndrome treatment market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
• What is the market segmentation based on type?
• What is the market breakup based on treatments?
• What is the market segmentation based on route of administration?
• What is the market breakup based on gender?
• What are the major end users in the market?
• What is the market breakup based on patient type?
• What are the major distribution channels?
• What factors influence the choice between intravenous immunoglobulin and plasma exchange as Guillain-Barre syndrome treatment options for patients?
• How does the preference for parenteral administration versus oral administration vary across different regions for Guillain-Barre syndrome treatment market?